Editorial
This editorial describes the results of the most recent clinical trials on the use of immunotherapies in renal cell carcinoma and research for reliable biomarkers of tumour response in this setting, as well as the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies.
Case Report
The case report discusses a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib.
Review
This article examines the major approaches to immunotherapy in breast cancers, both successes and failures, as well as new therapies on the horizon.
Original Research
This article examines the relationship between U.S. Food and Drug Administration (FDA) approval and the publication of OS evidence to understand better the risks and benefits of delaying approval until OS evidence is available.
Original Research
This retrospective study looks to find specific predictive criteria related to patient or tumor characteristics in order to select patients that might benefit the most from eribulin and define the correct treatment sequence.
